/
Integrated Programming for HIV and Integrated Programming for HIV and

Integrated Programming for HIV and - PowerPoint Presentation

pamella-moone
pamella-moone . @pamella-moone
Follow
346 views
Uploaded On 2019-11-09

Integrated Programming for HIV and - PPT Presentation

Integrated Programming for HIV and NonCommunicable Diseases Medication Adherence C lubs in Kibera and other stories Tom Ellman Southern Africa Medical Unit MSF TomEllmanjoburgmsforg Conflict of Interest ID: 765079

hiv oca ncd ocb oca hiv ocb ncd countries msf care ocg medication clubs kibera treatment hypertension patients median

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Integrated Programming for HIV and" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Integrated Programming for HIV and Non-Communicable Diseases Medication Adherence Clubs in Kibera and other stories Tom Ellman, Southern Africa Medical Unit, MSF Tom.Ellman@joburg.msf.org

Conflict of Interest No conflicts of interest to declare

What are we talking about? There are many NCDsFocus on hypertension, CVD, DM…..and fertilityCo-morbidityHIV patients with NCDsTB and DMOpportunity cost of treatment is relatively low Service delivery models Lifelong treatment ‘Wellness’ Differentiated approaches Integration or introduction?

NCDs came before HIV care

Zimbabwe Chipinge OCB South Sudan Agok OCG Aweil OCP Kenya : Kibera closing OCB/ Embu starting Daghaley OCG Afghanistan OCB/OCA Ukraine OCG /OCB Myanmar OCA Swaziland Manzini OCA DRC Mweso OCA ( Diabetes only) Ethiopia OCA MSF Projects with NCD Focus May 2017 Africa : 8 projects 6 countries Middle East : 3 countries Eastern Europe / Russia: 2 countries Central asia /Asia: 2 countries Lebanon OCB / OCB Jordan OCBA /OCA Iraq/Syria OCG/OCA Chechyna OCA ( DRTB) 13 countries 26,056 patients

HIV and NCD care in an informal setting in Kibera, Kenya Apply lessons from ART rollout to NCD cohorts 4,227 NCD patients enrolled by Nov 2014 70% (2,950) females Overall median age: 46 years (IQR: 38-54) 87 % (3,691) hypertensive , diabetes or both1Van de Vijver et al,2013; Ayah et al 2013

Success of treatment in Kibera Retention higher in HIV positive: 22% v 36% at 6 months Success after 6 months: 40 % of PLWHIV SBP < 140 50 % of HIV negative SBP < 140 37% PLHIV HBA1C<7%20% HIV negative HBA1C of < 7 %.

Task-shifting within NCD care

When? Every 3 months in the afternoons after work or Saturday morning Where? Most Meet At facility Who : faciliated lay worker Medication Adherence Clubs- Stable Adults (20-30 clients; facility based; lay worker led)

1432 enrolled into 47 clubs Offloaded 2,208 consultations from routine outpatient care Loss to follow up 3.5% 71% HIV positive 29% have Diabetes or Hypertension Medication Adherence Clubs- 2

All are lifelong diseases of mostly healthy people requiring daily treatment but… HIVYounger and deadlier Low NNT Activism and advocacy Simple treatments Standardised guidelines Simple affordable tools and formulations Assured quality drug supply Decentralised care Task-shifted careAnnual consultations and multi-month refillsDifferentiated service deliveryA Global Fund and free careCVD, hypertension, and DM

Access to NCD medications Survey 40 countries ( 2011)Cameron et al Medication class Public Sector ( median medicine availability %) Private sector ( median medicine availability %) Antidiabetics ( n=2)* 49.5 65.0 Antihypertensives (n=5) 34.7 57.1 Antiasthmatics ( n=2)30.143.1Antiepileptics ( n=2)29.440.3WHO just repeated surveys with new adapted tool in Mozambique , Ethiopia and DRC

Where next? Patient-centred demedicalised careSelf-managementCritical enablersNothing possible without……. free quality-assured accessible drugs Appropriate normative guidance and advocacy for simplification Pilots at scale

THANKS Acknowledge MSF Field teams and MoH colleaguesColleagues in SAMU, Access Campaign, MSF HQs